The mouse equivalent of the human p53ser249 mutation p53ser246 enhances aflatoxin hepatocarcinogenesis in hepatitis B surface antigen transgenic and p53 heterozygous null mice
- PMID: 9537435
- DOI: 10.1002/hep.510270411
The mouse equivalent of the human p53ser249 mutation p53ser246 enhances aflatoxin hepatocarcinogenesis in hepatitis B surface antigen transgenic and p53 heterozygous null mice
Abstract
The relative contribution to development of hepatocellular carcinoma of the mouse equivalent to the human p53ser249 mutation, found in human hepatocellular carcinoma associated with aflatoxin (AFB1) exposure, is compared with other major risk factors in a transgenic mouse model. Transgenic p53ser246 mice, expressing the mutant protein gene under the control of a truncated albumin promoter, were bred to mice lacking p53 (p53-/-) and to transgenic mice expressing hepatitis B surface antigen (HBsAg). AFB1 hepatocarcinogenesis was then determined in offspring with single or multiple risk factors by determination of the numbers of high-grade hepatic tumors at 13 months of age. In AFB1-treated male mice, expression of the p53ser246 mutation increases the incidence of high-grade tumors from 0% to 14% in HBsAg-negative, p53+/+ (wild-type homozygous) control mice; from 14% to 71% in HBsAg-negative, p53+/- (wild-type heterozygous) mice; and from 62% to 100% in HBsAg-positive, p53+/+ mice. Thus, whereas HBsAg expression and AFB1 together are strongly cocarcinogenic, the presence of the p53ser246 mutant not only significantly enhances this cocarcinogenic effect, it also increases tumorigenesis in AFB1-treated p53 heterozygous and homozygous mice not expressing HBsAg. The possibility that the p53ser246 mutant protein may act as a promoting agent for AFB1 hepatocarcinogenesis is discussed.
Similar articles
-
Hepatitis B injury, male gender, aflatoxin, and p53 expression each contribute to hepatocarcinogenesis in transgenic mice.Hepatology. 1998 Feb;27(2):383-91. doi: 10.1002/hep.510270211. Hepatology. 1998. PMID: 9462635
-
Control of mouse hepatocyte proliferation and ploidy by p53 and p53ser246 mutation in vivo.Hepatology. 1998 Jan;27(1):73-80. doi: 10.1002/hep.510270113. Hepatology. 1998. PMID: 9425920
-
Mouse models to study the interaction of risk factors for human liver cancer.Cancer Res. 2003 Nov 15;63(22):7553-62. Cancer Res. 2003. PMID: 14633666
-
[Molecular genetic and epigenetic mechanisms of hepatocarcinogenesis].Ai Zheng. 2005 Jun;24(6):757-68. Ai Zheng. 2005. PMID: 15946497 Review. Chinese.
-
The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect.Clin Ter. 2004 May;155(5):187-99. Clin Ter. 2004. PMID: 15344567 Review.
Cited by
-
Molecular characterization of hepatocarcinogenesis using mouse models.Dis Model Mech. 2015 Jul 1;8(7):743-53. doi: 10.1242/dmm.017624. Epub 2015 May 5. Dis Model Mech. 2015. PMID: 26035378 Free PMC article.
-
Loss of TP53 cooperates with c-MET overexpression to drive hepatocarcinogenesis.Cell Death Dis. 2023 Jul 27;14(7):476. doi: 10.1038/s41419-023-05958-y. Cell Death Dis. 2023. PMID: 37500626 Free PMC article.
-
Mycotoxins and human disease: a largely ignored global health issue.Carcinogenesis. 2010 Jan;31(1):71-82. doi: 10.1093/carcin/bgp264. Epub 2009 Oct 29. Carcinogenesis. 2010. PMID: 19875698 Free PMC article.
-
Mutant p53 in cancer therapy-the barrier or the path.J Mol Cell Biol. 2019 Apr 1;11(4):293-305. doi: 10.1093/jmcb/mjy072. J Mol Cell Biol. 2019. PMID: 30508182 Free PMC article. Review.
-
Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma.Gastroenterology. 2011 Mar;140(3):1063-70. doi: 10.1053/j.gastro.2010.11.034. Epub 2010 Nov 19. Gastroenterology. 2011. PMID: 21094160 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous